title: Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.
abstract: BACKGROUND
  The aim of this study was to determine the role of hepatitis B virus (HBV) vaccination as defined by the seroconversion to hepatitis B surface antibody (anti-HBs) positivity in peripheral blood stem cell transplants.
  
  
  METHODS
  A total of 65 recipients and their donors were enrolled in this study. Recipients were divided into four distinct groups. Group 1 consisted of individuals who were vaccinated, group 2 consisted of individuals who were naturally immunized, group 3 consisted of individuals who were HBs-Ag positive, and group 4 consisted of individuals who were HBV naïve and not vaccinated.
  
  
  RESULTS
  Eighty-eight percent of the HBV-vaccinated recipients (14 of 16), who had vaccinated-donors, seroconverted to anti-HBs positivity. Eighty-three percent of HBV-naïve recipients (five of six), who received stem cells from HBV-immune donors, seroconverted to anti-HBs positivity. Two of the four HBs-Ag positive recipients with HBV-immune donors seroconverted to anti-HBs positivity after transplantation. Fifty-seven percent of previously vaccinated-recipients (eight of 14) lost detectable anti-HBs antibody following transplantation. Finally, 31% of HBV-naïve recipients with HBV-naïve donors acquired a de novo HBV infection.
  
  
  CONCLUSIONS
  (i) Hepatitis B virus immunization of recipients of allogeneic hematopoietic cell transplantation results in an effective antibody response. (ii) The HBV-immune status of the donor plays an important role in post-transplantation HBs-Ab on seroconversion. (iii) Systematic re-immunization of recipients will be necessary to maintain HBV immunity in long-term serving recipients.
authors.affiliation: Department of Gastroenterology, Ankara University Medical School, Ibn'i Sina Hospital, Sihhiye, Ankara, Turkey. idilman1@hotmail.com
authors.forename: Ramazan
authors.initials: R
authors.lastname: Idilman
authors.forename: Celalettin
authors.initials: C
authors.lastname: Ustün
authors.forename: Selim
authors.initials: S
authors.lastname: Karayalçin
authors.forename: Aslihan
authors.initials: A
authors.lastname: Aktemel
authors.forename: Ahmet R
authors.initials: AR
authors.lastname: Turkyilmaz
authors.forename: Muhit
authors.initials: M
authors.lastname: Ozcan
authors.forename: Onder
authors.initials: O
authors.lastname: Arslan
authors.forename: A Mithat
authors.initials: AM
authors.lastname: Bozdayi
authors.forename: David H
authors.initials: DH
authors.lastname: Van Thiel
authors.forename: Hamdi
authors.initials: H
authors.lastname: Akan
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D007113:Immunity, Innate; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011300:Preoperative Care; D014019:Tissue Donors; D014611:Vaccination
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens